Juvabis AG

Juvabis is a clinical-stage biopharmaceutical startup that develops next-generation antimicrobial therapeutics against highly drug resistant infections. Juvabis holds an exclusive worldwide license for a strong IP portfolio invented at the ETH and University of Zurich by its co-founders. Juvabis has the most advanced antibiotic asset within the Innovative Medicines Initiative ENABLE program, having advanced to Phase-1, first-in-human, clinical trials (scheduled to conclude early 2021). Juvabis currently offers the opportunity for investors to finance Phase 2 clinical trials for its lead asset, whilst advancing the company's preclinical pipeline.